-
Product Insights
NewNet Present Value Model: Novo Nordisk AS’s HS-001
Empower your strategies with our Net Present Value Model: Novo Nordisk AS's HS-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Novo Nordisk AS’s HS-001
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval Analysis for Hidradenitis Suppurativa
Overview How likely is it that the drugs in Hidradenitis Suppurativa will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hidradenitis Suppurativa Overview Hidradenitis suppurativa (HS) is a chronic skin condition that...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SBT-777101 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SBT-777101 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SBT-777101 in Rheumatoid Arthritis Drug Details: SBT-777101 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orismilast in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orismilast in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orismilast in Ulcerative Colitis Drug Details: Orismilast (UNI-50001) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orismilast in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orismilast in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orismilast in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: Orismilast (UNI-50001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orismilast in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orismilast in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orismilast in Atopic Dermatitis (Atopic Eczema) Drug Details: Orismilast (UNI-50001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-442970 in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAR-442970 in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAR-442970 in Hidradenitis Suppurativa Drug Details: SAR-442970 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HS-001 in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HS-001 in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HS-001 in Systolic Heart Failure Drug Details:HS-001 is under development for the...